Medpace Holdings, Inc. $MEDP Shares Purchased by Caisse DE Depot ET Placement DU Quebec

Key Points

• Caisse DE Depot ET Placement DU Quebec has increased its stake in Medpace Holdings, Inc. by 32.1% in the first quarter, owning approximately 0.80% of the company, worth about $70.2 million.
• Analysts have mixed ratings on Medpace, with Barclays setting a new price target of $450 while UBS downgraded it to a "sell" rating with a slightly higher target of $305.
• Medpace reported a quarterly earnings of $3.10 EPS, exceeding analysts' expectations, with revenue growing 14.2% year-over-year to $603.31 million.

Caisse DE Depot ET Placement DU Quebec grew its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 32.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 230,524 shares of the company's stock after purchasing an additional 55,955 shares during the period. Caisse DE Depot ET Placement DU Quebec owned approximately 0.80% of Medpace worth $70,238,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Brooklyn Investment Group lifted its holdings in Medpace by 244.8% in the first quarter. Brooklyn Investment Group now owns 100 shares of the company's stock valued at $30,000 after acquiring an additional 71 shares during the last quarter. Whittier Trust Co. lifted its stake in Medpace by 47.3% during the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock worth $33,000 after purchasing an additional 35 shares in the last quarter. Colonial Trust Co SC lifted its stake in Medpace by 150.0% during the fourth quarter. Colonial Trust Co SC now owns 175 shares of the company's stock worth $58,000 after purchasing an additional 105 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new position in Medpace during the first quarter worth $60,000. Finally, Assetmark Inc. lifted its stake in Medpace by 24.9% during the first quarter. Assetmark Inc. now owns 216 shares of the company's stock worth $66,000 after purchasing an additional 43 shares in the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Medpace

In other Medpace news, CEO August J. Troendle sold 48,487 shares of the firm's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $451.69, for a total transaction of $21,901,093.03. Following the transaction, the chief executive officer owned 962,615 shares of the company's stock, valued at approximately $434,803,569.35. This trade represents a 4.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Kevin M. Brady sold 12,000 shares of the firm's stock in a transaction dated Thursday, July 24th. The stock was sold at an average price of $454.23, for a total value of $5,450,760.00. Following the transaction, the chief financial officer directly owned 6,000 shares in the company, valued at approximately $2,725,380. The trade was a 66.67% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 115,070 shares of company stock valued at $52,085,751. Corporate insiders own 20.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on MEDP shares. Mizuho upped their price target on Medpace from $328.00 to $510.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. Cowen cut Medpace from a "buy" rating to a "sell" rating in a research note on Wednesday, July 23rd. UBS Group cut Medpace from a "neutral" rating to a "sell" rating and upped their price target for the stock from $300.00 to $305.00 in a research note on Tuesday, July 29th. TD Cowen restated a "sell" rating and set a $366.00 price target (up from $283.00) on shares of Medpace in a research note on Wednesday, July 23rd. Finally, Barclays upped their price target on Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 23rd. Two research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Reduce" and an average price target of $406.60.

Medpace Trading Down 0.1%

NASDAQ:MEDP traded down $0.54 during trading hours on Thursday, hitting $472.94. The company's stock had a trading volume of 202,838 shares, compared to its average volume of 356,826. The stock has a market capitalization of $13.28 billion, a P/E ratio of 35.16, a price-to-earnings-growth ratio of 2.98 and a beta of 1.42. The stock has a fifty day moving average of $392.42 and a 200-day moving average of $338.34. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $501.30.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating the consensus estimate of $3.00 by $0.10. The firm had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.Medpace's revenue for the quarter was up 14.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.